摘要
目的:应用枸橼酸铋雷尼替丁(RBC)或埃索美拉唑(EMO)分别与克拉霉素(C)+阿莫西林(A)三联7天疗法根除HP,评估以RBC为基础的三联方案的疗效。方法:40例功能性消化不良患者随机分配至A组或B组,每组20例,A组为RBC 0.2 g+C 0.5 g+A1 g,bid,口服;B组为EMO20 mg+C 0.5 g+A1 g,bid,口服,疗程7 d。停药28 d后检查13C尿素呼气试验,如阴性表示根除成功,观察两组HP阴转率。结果:两组HP阴转率分别为85%和80%,差异无显著性(P>0.05)。患者依从性好,均未见严重不良反应。结论:RBC或EMO三联疗法根除HP,其HP阴转率A组略高于B组,RBC三联疗法根除HP疗效好。
Objective ：To compare the eradication rates in helicobacter pylori （HP） infection of two triple therapies. Methods：Forty patients with non-ulcer dyspepsias were randomized into 2 groups. Group A was given with ranitidine bismuth citrate（RBC）0.2 g bid plus elarithromycin（C ）0.5 g bid and amoxicillin（A） 1.0 g bid po for one week. Group B was treated with esomeprazole 20 mg bid plus clarithromycin （ C ） 0.5 g bid and amoxicillin （A） 1.0 g bid po for one week. Rapid urease test was repeated one month after anti-HP therapy. Results：The eradication rates of group A and group B were 85% and 80%, respectively. No significant difference was found between two group （P 〉 0.05 ）. Patient compliance was good. No serious adverse reactions were reported. Conclusion ： The regimen of triple therapy with RBC is better than regimen with EMO for the clinical eradication of HP infection.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2008年第6期515-517,共3页
Chinese Journal of New Drugs
关键词
枸橼酸铋雷尼替丁
三联疗法
幽门螺杆菌
疗效
ranitidine bismuth
triple therapies
helicobacter pylori（HP）
efficacy
